Ionis Pharmaceuticals (IONS) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ionis Pharmaceuticals (IONS)

IONS 82.67

-1.4%

Jan 30 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: bob zagorin who wrote (4590)	8/4/2010 5:42:36 PM
From: bob zagorin	of 4676

anyone care to comment on this thesis.. blinded study. patients don't know how much efficacy they are getting so there's no reinforcement to continue. in real world, with monitoring showing cholesterol lowering they they would keep going.. also there is no individual dose adjustment to account for liver issues. in real world, docs will adjust dose and balance risk / reward and thus could rx off-label to broader population?

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next